Navigation

Researchers at UCD

researcher

Michael Duffy

Professor (Adjunct)

School of Medicine & Medical Science
Clinical Research Centre,
St Vincent's University Hospital
Dublin 4

Tel: 353-1-7165814
Email: michael.j.duffy@ucd.ie

Professional

Honours and Awards

Year: 2102.
Title: Abbott Award

Associations

Association: European Group on Tumor Markers (EGTM), Function/Role: Board member
Association: American Association for Cancer Research (AACR), Function/Role: Member
Association: International Society of Oncology and Biomarkers, Function/Role: Board Member
Association: National Academy of Clinical Biochemistry, Function/Role: Chair of committee for preparing guidelines on tumor markers in breast cancer
Association: National Academy of Clinical Biochemistry (USA), Function/Role: Stering committee member for preparing guidelines on tumor markers
Association: European Group on Tumor Markers, Function/Role: Leader of Gastrointestinal Focus Group
                       

Publications

 

Book Chapters

MJ Duffy, M Mullooly, J Crown, PM McGowan (2013) 'The ADAMs: new Therapeutic Targets for Cancer' In: YH Bae, RJ Mrsny, K Park (eds). Cancer Targeted Drug Delivery. New York: Springer. [Details]
Duffy MJ (2002) 'Proteases in Cancer: Markers of Metastatic Potential and Prognosis' In: Diamindis, Fritsche, Lija, Chan & Schwartz (eds). Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington: American Association Of Clinical Chemistry (AACC) Press. [Details]
Duffy MJ (2012) 'Use of Tumor markers in the Detection and Management of Patients with Colorectal Cancer' In: C H Cho and J Yu (eds). From Inflammation to Cancer: Advances in Diagnosis and Therapy for Gastrointestinal and Hepatological Disease. New Jersey, London, Singapore: World Scientific. , pp.315-330 [Details]
Duffy MJ; (2009) 'Biomarkers in breast cancer: use in aiding diagnosis, determining prognosis and predicting response to therapy' In: Adit Ben-Baruch (eds). Breast Cancer: From Pathogenesis to Potential Therapeutic Modalities. Kerala, India: Transworld Research Network. , pp.211-227 [Details]
 

Peer Reviewed Journals

Duffy MJ, Schwarz V; (1973) 'Calcium binding by the erythrocyte membrane'. Biochimica et biophysica acta, 330 (3):294-301. [Details]
Cantwell B, Duffy MJ, Fennelly JJ, Jones M, Duffy G, Daly L; (1980) 'Carcino-embryonic antigen assay as a guide to tumour bulk, response to therapy and prognosis in human breast cancer'. Journal Of Medicine, 149 (12):469-474. [Details]
Cantwell B, Duffy MJ, Mehigan JA, Fennelly JJ; (1981) 'Persisting and gross elevation of serum carcinoembryonic antigen levels after removal of tumour bulk'. Clinical oncology, 7 (1):59-60. [Details]
Farrell RJ, Duffy MJ, Duffy GJ, Callan F, McKenna TJ; (1982) 'The free T3 index in familial TBG deficiency'. Clinica chimica acta; international journal of clinical chemistry, 118 (1):121-123. [Details]
Duffy MJ; (1982) 'Molecular biology in medicine'. Journal Of Medicine, 151 (4):114-122. [Details]
Farrell RJ, Duffy MJ, Hynes N, Groarke Y, Drumm A, Ni Gogain N, Wilson A, Duffy GJ; (1982) 'Routine measurement of free thyroxine by a kinetic-based assay'. Irish Medical Journal, 75 (6):206-209. [Details]
Duffy MJ, O'Sullivan F, McDonnell TJ, FitzGerald MX; (1985) 'Increased concentrations of the antigen CA-19-9 in serum of cystic fibrosis patients'. Clinical Chemistry, 31 (7):1245-1246. [Details]
Duffy MJ, O'Sullivan F, O'Donoghue D, Afdhal NH, Kelleher D; (1985) 'Ca-19-9, a new marker for gastrointestinal malignancy'. Journal Of Medicine, 154 (10):385-386. [Details]
Nugent A, McDermott E, Duffy K, O'Higgins N, Fennelly JJ, Duffy MJ; (1992) 'Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer'. Clinical Chemistry, 38 (8 Pt 1):1471-1474. [Details]
Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA; (1992) 'Type-1 plasminogen activator inhibitor in human breast carcinomas'. INT J CANCER, 50 (2):208-214. [Details]
Duffy MJ; (1993) 'Cellular oncogenes and suppressor genes as prognostic markers in cancer'. Clinical Biochemistry, 26 (6):439-447. [Details]
Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermott E, Fennelly JJ, O'Higgins N; (1996) 'Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer'. Enzyme, 49 (1-3):85-93. [Details]
Duffy MJ; (1996) 'Proteases as prognostic markers in cancer'. Clinical cancer research : an official journal of the American Association for Cancer Research, 2 (4):613-618. [Details]
Duffy MJ; (1996) 'PSA as a marker for prostate cancer: a critical review'. Clinical Biochemistry, 33 ( Pt 6) :511-519. [Details]
Chenard MP, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq JP, Duffy MJ; (1996) 'High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma'. INT J CANCER, 69 (6):448-451. [DOI] [Details]
Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Donoghue DP, Sheahan K; (1997) 'Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome'. Clinical cancer research : an official journal of the American Association for Cancer Research, 3 (10):1837-1840. [Details]
Kennedy S, Duffy MJ, Duggan C, Barnes C, Rafferty R, Kramer MD; (1998) 'Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry'. British Journal of Cancer, 77 (10):1638-1641. [Details]
Remacle AG, Noël A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ (1998) 'Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer'. British Journal of Cancer, 77 (6):926-931. [Details]
Shering SG, Sherry F, McDermott EW, O'Higgins NJ, Duffy MJ; (1998) 'Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma'. Cancer, 83 (12):2521-2527. [Details]
Cullen R, MaGuire T, Diggin P, Hill A, McDermott E, O'Higgins N, Duffy MJ; (2000) 'Detection of estrogen receptor-beta mRNA in breast cancer using RT-PCR'. The International journal of biological markers, 15 (1):114-115. [Details]
Price CP, Allard J, Davies G, Dawnay A, Duffy MJ, France M, Mandarino G, Ward AM, Patel B, Sibley P, Sturgeon C; (2001) 'Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer'. Clinical Biochemistry, 38 (Pt 3):188-216. [Details]
Berglöf T, Koskinen WC, Duffy MJ, Norberg KA, Kylin H (2003) 'Metsulfuron methyl sorption-desorption in field-moist soils'. FOOD CHEM, 51 (12):3598-3603. [DOI] [Details]
Duffy MJ, Duggan C; (2004) 'The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer'. Clinical Biochemistry, 37 (7):541-548. [DOI] [Details]
Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP; (2004) 'Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression'. European journal of cancer (Oxford, England : 1990), 40 (10):1610-1616. [DOI] [Details]
O'Brien NA, O'Donovan N, Ryan B, Hill AD, McDermott E, O'Higgins N, Duffy MJ; (2005) 'Mammaglobin a in breast cancer: existence of multiple molecular forms'. INT J CANCER, 114 (4):623-627. [DOI] [Details]
Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P (2005) 'Tumor markers in breast cancer- European Group on Tumor Markers recommendations'. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 26 (6):281-293. [DOI] [Details]
Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ (2005) 'Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration'. Oncology Reports, 14 (1):235-239. [Details]
Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L; (2010) 'Intracellular and Extracellular MicroRNAs in Breast Cancer'. Clinical Chemistry, . [DOI] [Details]
O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ; (2010) 'Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib'. MOL CANCER, 9 (6):1489-1502. [DOI] [Details]
Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM (2010) 'Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer'. BMC Cancer, 10 . [DOI] [Details]
Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP (2010) 'National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers'. Clinical Chemistry, 56 (6):1-48. [DOI] [Details]
Nicolini A, Ferrari P, Duffy MJ, Antonelli A, Rossi G, Metelli MR, Fulceri F, Anselmi L, Conte M, Berti P, Miccoli P (2010) 'Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival'. Archives of surgery (Chicago, Ill. : 1960), 145 (12):1177-1183. [DOI] [Details]
Duffy MJ, Crown J (2013) 'Companion biomarkers: paving the pathway to personalized treatment for cancer'. Clinical chemistry, 59 (10):1447-1456. [DOI] [Details]
O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM (2013) 'Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer'. BMC Cancer, 13 . [DOI] [Details]
Duffy MJ, Schwarz V; (1972) 'Phosphorylation of the erythrocyte membrane: stimulation by adenosine 3':5'-cyclic monophosphate'. The Biochemical journal, 126 (3):1-1. [Details]
Duffy MJ, Schwarz V; (1972) 'Cystic fibrosis and membrane transport'. Lancet, 2 (7768):136-137. [Details]
Lloyd G, Dacie JE, Duffy MJ; (1973) 'Axial tomography of the orbits and paranasal sinuses'. The British journal of radiology, 46 (542). [Details]
Duffy MJ, Schwarz V; (1973) 'Cyclic AMP stimulated phosphorylation of erythrocyte membranes from cystic fibrosis and control subjects'. Clinica chimica acta; international journal of clinical chemistry, 49 (3):397-399. [Details]
Duffy MJ, Duffy GJ; (1977) 'Studies on the labeling of streptokinase with 99mTc for use as a radiopharmaceutical in the detection of deep-vein thrombosis: concise communication'. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 18 (5):483-485. [Details]
Duffy MJ, Duffy GJ; (1978) 'Estradiol receptors in human liver'. Journal of steroid biochemistry, 9 (3):233-235. [Details]
Duffy MJ, Duffy GJ; (1978) 'Multiple steroid receptors in male breast carcinomas'. Clinica chimica acta; international journal of clinical chemistry, 85 (2):211-214. [Details]
Duffy MJ, Hynes N, Groarke Y, Oliver J, O'Broin A, Duffy G; (1978) 'Biochemical markers in breast carcinoma'. Irish Medical Journal, 71 (12):408-413. [Details]
Duffy MJ, Duffy GJ; (1979) 'Studies on progesterone receptors in human breast carcionomas: use of natural and synthetic ligands'. European journal of cancer (Oxford, England : 1990), 15 (10):1181-1184. [Details]
Hogan-Ryan A, Fennelly JJ, Jones M, Cantwell B, Duffy MJ; (1980) 'Serum sialic acid and CEA concentrations in human breast cancer'. British Journal of Cancer, 41 (4):587-592. [Details]
Duffy MJ; (1980) 'Measurement of progesterone receptors in human breast tumors using the synthetic progestin 16 alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione'. Journal of steroid biochemistry, 13 (9):1005-1007. [Details]
Duffy MJ, McGarry Y, Hynes N, Duffy GJ, Tobin MJ, Fitzgerald MX; (1980) 'Decreased immunoreactive trypsin levels in sera from cystic fibrosis patients'. Clinica chimica acta; international journal of clinical chemistry, 103 (2):233-235. [Details]
Farrell RJ, Duffy MJ, Moriarty MJ, Duffy GJ; (1980) 'Plasma concentrations of the platelet-specific beta-thromboglobulin in malignant disease'. British Journal of Cancer, 41 (6):989-991. [Details]
Duffy MJ; (1980) 'Estradiol and progesterone receptors in human breast tumours'. Irish Medical Journal, 73 (8):311-312. [Details]
Duffy MJ, O'Connell M; (1981) 'Estrogens, estradiol receptors and peroxidase activity in human mammary carcinomas'. European journal of cancer (Oxford, England : 1990), 17 (6):711-714. [Details]
Shridhar P, Duff FA, Kelly DG, Allen-Davis AM, Duffy MJ, Duffy GJ; (1981) 'Rectal examination and acid phosphatase'. Clinical Research, 283 (6289). [Details]
Tobin MJ, Duffy MJ, Duffy G, FitzGerald MX; (1981) 'Serum immuno reactive trypsin and pancreatic isoamylase in older patients with cystic fibrosis'. Journal Of Medicine, 150 (11):325-328. [Details]
Duffy MJ; (1982) 'Assay of estradiol receptors in human breast carcinomas using the gamma emitting ligand 16 alpha [125I]iodoestradiol'. Journal of steroid biochemistry, 16 (2):343-344. [Details]
O'Connell M, McDonnell L, Duffy MJ; (1982) 'Studies on nuclear estradiol receptors in human mammary carcinomas'. Clinica chimica acta; international journal of clinical chemistry, 119 (3):285-289. [Details]
Duffy MJ, O'Connell M, McDonnel L; (1982) 'Peroxidase activity in human breast carcinomas: correlation with histological and biochemical parameters'. European journal of cancer (Oxford, England : 1990), 18 (5):453-455. [Details]
Farrell RJ, Duffy MJ, Duffy GJ; (1982) 'Serum fragment E and plasma beta-thromboglobulin in patients with acute pulmonary embolism and non-thromboembolic lung diseases'. Thrombosis Research, 27 (2):231-234. [Details]
Duffy MJ, O'Connell M, O'Sullivan F, McKenna B, Allen MA, McDonnell L; (1983) 'CEA-like material in cytosols from human breast carcinomas. Correlation with biochemical and pathologic parameters'. Cancer, 51 (1):121-123. [Details]
Duffy MJ, Tuttlebee J, O'Sullivan F, Allen-Davis M; (1983) 'Evaluation of assays for thyroxine, triodotyronine and thyroid-stimulating hormone on the ARIA II automated radioimmunoassay instrument'. The Journal of automatic chemistry, 5 (1):43-44. [DOI] [Details]
Callan FP, Duffy MJ, Duffy GJ, Farrell RJ, McKenna TJ; (1983) 'Thyroid function in goitrous subjects with thyroxine binding globulin deficiency'. Acta Endocrinologica, 102 (4):527-530. [Details]
Duffy MJ, O'Connell M, McDonnell L; (1984) 'Peroxidase activity as a marker for estrogen action in rat uteri and human mammary carcinomas'. Cancer Research, 91 :283-288. [Details]
Duffy MJ; (1984) 'A biochemical approach to cancer management'. Journal Of Medicine, 153 (9):297-301. [Details]
Duffy MJ, O'Grady P; (1984) 'Plasminogen activator and cancer'. European journal of cancer (Oxford, England : 1990), 20 (5):577-582. [Details]
Duffy MJ, O'Connell M, McDonnell L, Connolly CE, Cantwell B, Fennelly JJ, Conroy R; (1984) 'Studies on estradiol receptors in human mammary carcinomas'. Journal Of Medicine, 153 (11):381-384. [Details]
O'Grady P, Lijnen HR, Duffy MJ; (1985) 'Multiple forms of plasminogen activator in human breast tumors'. Cancer Research, 45 (12 Pt 1):6216-6218. [Details]
Duffy MJ, O'Grady P, Simon J, Rose M, Lijnen HR; (1986) 'Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors'. Cancer, 77 (3):621-623. [Details]
Duffy MJ, O'Siorain L, Waldron B, Smith C; (1986) 'Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies'. Clinical Chemistry, 32 (10):1972-1974. [Details]
Heaney JA, Allen MA, Keane T, Duffy MJ; (1987) 'Prostate-specific antigen. Superior serum marker for prostatic carcinoma'. Journal Of Medicine, 156 (5):138-141. [Details]
Duffy MJ; (1987) 'Do proteases play a role in cancer invasion and metastasis?'. European journal of cancer (Oxford, England : 1990), 23 (5):583-589. [Details]
Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HR; (1988) 'Tissue-type plasminogen activator, a new prognostic marker in breast cancer'. Cancer Research, 48 (5):1348-1349. [Details]
Johnston P, Dervan P, McAllister M, Duffy MJ, Carney DN; (1988) 'Immunohistochemical analysis of breast cancer oestrogen receptor status and its correlation with oestrogen receptor biochemical assay'. Journal Of Medicine, 157 (7):226-228. [Details]
Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ; (1988) 'Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report'. Cancer, 62 (3):531-533. [Details]
Sheehan JD, Duffy MJ, Allen MA, Fennelly JJ; (1989) 'CA 125 as a tumour marker in epithelial ovarian cancer'. Journal Of Medicine, 158 (1):10-13. [Details]
Duffy MJ; (1989) 'New cancer markers'. Clinical Biochemistry, 26 ( Pt 5) :379-387. [Details]
Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ; (1990) 'Urokinase plasminogen activator and prognosis in breast cancer'. Lancet, 335 (8681). [Details]
Duffy MJ; (1990) 'Biochemical markers as prognostic indices in breast cancer'. Clinical Chemistry, 36 (2):188-191. [Details]
Cronin C, Igoe D, Duffy MJ, Cunningham SK, McKenna TJ; (1990) 'The overnight dexamethasone test is a worthwhile screening procedure'. Clinical Endocrinology, 33 (1):27-33. [Details]
Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P; (1990) 'Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer'. Cancer Research, 50 (21):6827-6829. [Details]
Duffy MJ, Brouillet JP, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Maudelonde T, Rochefort H; (1991) 'Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings'. Clinical Chemistry, 37 (1):101-104. [Details]
Reilly D, Andreasen P, Duffy MJ; (1991) 'Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level'. Biochemical Society Transactions, 19 (1). [Details]
Reilly D, Andreasen PA, Duffy MJ; (1991) 'Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay'. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2 (1):47-50. [Details]
Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ; (1992) 'CA 15-3 in patients with locoregional and metastatic breast carcinoma'. Cancer, 70 (12):2831-2834. [Details]
Reilly DM, Andreasen PA, Duch M, Nolan N, Lecander I, Duffy MJ; (1992) 'Plasminogen activator inhibitor type 1 and 2 in human breast cancer'. Biochemical Society Transactions, 20 (1). [Details]
Nugent A, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ; (1992) 'Measurement of erbB-2 oncoprotein in human breast cancers by ELISA'. Biochemical Society Transactions, 20 (1). [Details]
Duffy MJ, Reilly D, Brouillet JP, McDermott EW, Faul C, O'Higgins N, Fennelly JJ, Maudelonde T, Rochefort H; (1992) 'Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival'. Clinical Chemistry, 38 (10):2114-2116. [Details]
Duffy MJ; (1992) 'Inhibiting tissue invasion and metastasis as targets for cancer therapy'. Biotherapy (Dordrecht, Netherlands), 4 (1):45-52. [Details]
Igoe D, Duffy MJ, McKenna TJ; (1992) 'TSH as an index of L-thyroxine replacement and suppression therapy'. Journal Of Medicine, 161 (12):684-686. [Details]
Reynolds JV, Sweeney JP, Nolan N, Korebrits A, Duffy MJ, McDermott EW, O'Higgins NJ; (1993) 'Management of ductal carcinoma in situ of the breast'. Journal Of Medicine, 162 (2):45-48. [Details]
Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Andreasen PA; (1994) 'Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer'. Cancer, 74 (8):2276-2280. [Details]
Nugent A, Gallagher J, Dolan J, O'Higgins N, Duffy MJ; (1994) 'Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer'. Clinical Biochemistry, 31 ( Pt 2) :171-173. [Details]
Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ; (1995) 'Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer'. INT J CANCER, 61 (5):597-600. [Details]
Duffy MJ, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly JJ, Tschesche H; (1995) 'Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer'. British Journal of Cancer, 71 (5):1025-1028. [Details]
Coveney EC, Geraghty JG, Sherry F, McDermott EW, Fennelly JJ, O'Higgins NJ, Duffy MJ; (1995) 'The clinical value of CEA and CA 15-3 in breast cancer management'. The International journal of biological markers, 10 (1):35-41. [Details]
Duffy MJ; (1995) 'Can molecular markers now be used for early diagnosis of malignancy?'. Clinical Chemistry, 41 (10):1410-1413. [Details]
Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N, Duffy MJ; (1997) 'Plasminogen activator inhibitor type 2 in breast cancer'. British Journal of Cancer, 76 (5):622-627. [Details]
Andreasen PA, Kjøller L, Christensen L, Duffy MJ (1997) 'The urokinase-type plasminogen activator system in cancer metastasis: a review'. INT J CANCER, 72 (1):1-22. [Details]
Maguire TM, Shering SG, McDermott EW, O'Higgins N, Fennelly JJ, Crown J, Duffy MJ; (1997) 'Assay of E-cadherin by ELISA in human breast cancers'. European journal of cancer (Oxford, England : 1990), 33 (3):404-408. [Details]
Duffy MJ, Duggan C; (1997) 'Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines'. Cancer, 89 (21):1628-1630. [Details]
Duffy MJ; (1998) 'Cancer metastasis: biological and clinical aspects'. Journal Of Medicine, 167 (1):4-8. [Details]
Sweep CG, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJ, Schmitt M, Duffy MJ, Jänicke F, Kramer MD, Foekens JA, Brünner N, Brugal G, Pedersen AN, Benraad TJ (1998) 'External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts'. British Journal of Cancer, 78 (11):1434-1441. [Details]
Duffy MJ; (1998) 'CA 19-9 as a marker for gastrointestinal cancers: a review'. Clinical Biochemistry, 35 ( Pt 3) :364-370. [Details]
Maguire TM, Shering SG, Duggan CM, McDermott EW, O'Higgins NJ, Duffy MJ; (1998) 'High levels of cathepsin B predict poor outcome in patients with breast cancer'. The International journal of biological markers, 13 (3):139-144. [Details]
McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ; (1999) 'High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer'. INT J CANCER, 84 (1):44-48. [Details]
Maguire T, Chin D, Soutar D, Duffy MJ; (2000) 'Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin'. INT J CANCER, 85 (4):457-459. [Details]
Remacle A, McCarthy K, Noël A, Maguire T, McDermott E, O'Higgins N, Foidart JM, Duffy MJ (2000) 'High levels of TIMP-2 correlate with adverse prognosis in breast cancer'. INT J CANCER, 89 (2):118-121. [Details]
Cullen R, Maguire TM, McDermott EW, Hill AD, O'Higgins NJ, Duffy MJ; (2001) 'Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer'. European journal of cancer (Oxford, England : 1990), 37 (9):1118-1122. [Details]
Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA (2002) 'Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients'. Cancer, 94 (2):116-128. [Details]
O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, O'Higgins N, Duffy MJ; (2002) 'Mammaglobin a: a promising marker for breast cancer'. Clinical Chemistry, 48 (8):1362-1364. [Details]
Schmitt M, Harbeck N, Daidone MG, Brynner N, Duffy MJ, Foekens JA, Sweep FC; (2004) 'Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer'. International Journal of Oncology, 25 (5):1397-1406. [Details]
Krajewska M, Kim H, Shin E, Kennedy S, Duffy MJ, Wong YF, Marr D, Mikolajczyk J, Shabaik A, Meinhold-Heerlein I, Huang X, Banares S, Hedayat H, Reed JC, Krajewski S; (2005) 'Tumor-associated alterations in caspase-14 expression in epithelial malignancies'. Clinical cancer research : an official journal of the American Association for Cancer Research, 11 (15):5462-5471. [DOI] [Details]
Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, Allen NE; (2005) 'Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis'. EUR UROL, 48 (3):386-31. [DOI] [Details]
Al-azawi D, Kelly G, Myers E, McDermott EW, Hill AD, Duffy MJ, Higgins NO; (2006) 'CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer'. BMC Cancer, 6 . [DOI] [Details]
Savinov AY, Remacle AG, Golubkov VS, Krajewska M, Kennedy S, Duffy MJ, Rozanov DV, Krajewski S, Strongin AY; (2006) 'Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients'. Cancer Research, 66 (5):2716-2724. [DOI] [Details]
Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM; (2007) 'Survivin: a promising tumor biomarker'. CANCER LETT, 249 (1):49-60. [DOI] [Details]
McGowan PM, Duffy MJ; (2008) 'Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database'. Annals of Oncology, 19 (9):1566-1572. [DOI] [Details]
Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC; (2008) 'Bcl-B expression in human epithelial and nonepithelial malignancies'. Clinical cancer research : an official journal of the American Association for Cancer Research, 14 (10):3011-3021. [DOI] [Details]
Pierce A, Saldova R, Abd Hamid UM, Abrahams JL, McDermott EW, Evoy D, Duffy MJ, Rudd PM; (2010) 'Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients'. Glycobiology, 20 (10):1283-1288. [DOI] [Details]
Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM (2011) 'The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?'. Proteomics, 8 (1). [DOI] [Details]
Duffy MJ (2011) 'Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?'. Clinical Biochemistry, 48 (Pt 4):310-316. [DOI] [Details]
McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ (2011) 'The role of S100 genes in breast cancer progression'. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 32 (3):441-450. [DOI] [Details]
Duffy MJ (2012) 'Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers'. Medycyna pracy, . [DOI] [Details]
Duffy MJ, McGowan PM, Crown J (2012) 'Targeted therapy for triple-negative breast cancer: Where are we?'. INT J CANCER, 131 (11):2471-2477. [DOI] [Details]
Duffy Michael (2013) 'Investigation of Molecular Alterations of AKT-3 in Triple Negative Breast Cancer'. Histopathology, . [Details]
Duffy Michael (2013) 'Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines'. Cancer Biology & Therapy, . [Details]
Dolly JO, Dillon A, Duffy MJ, Fottrell PF; (1971) 'Further studies on multiple forms of peptidases in mammalian tissues including intestinal mucosa from children with treated and untreated coeliac disease'. Clinica chimica acta; international journal of clinical chemistry, 31 (1):55-62. [Details]
Duffy MJ, Comer D, Schwarz V; (1973) 'Serum binding of Ca2+ and cystic fibrosis'. Nature: New biology, 246 (153). [Details]
Duffy MJ, Cohn EV, Schwarz V; (1974) 'Ca2+ uptake and binding by isolated erythrocyte membranes from cystic fibrosis and control subjects'. Clinica chimica acta; international journal of clinical chemistry, 50 (1):97-101. [Details]
Duffy MJ; (1974) 'Letter: Na+ transport defect in cystic fibrosis'. Nature, 249 (452):94-95. [Details]
Duffy MJ, Schwarz V; (1974) 'Hormone and adenosine 3', 5' cyclic monophosphate stimulated phosphorylation of human erythrocyte membranes'. BIOCHEM PHARMACOL, 23 (17):2464-2466. [Details]
Duffy MJ, Powell D; (1974) 'Letter: Cyclic A.M.P., substance P, and morphine analgesia'. Lancet, 2 (7892). [Details]
Duffy MJ, Powell D; (1975) 'Stimulation of brain adenylate cyclase activity by the undecapeptide substance P and its modulation by the calcium ion'. Biochimica et biophysica acta, 385 (2):275-280. [Details]
Duffy MJ, Wong J, Powell D; (1975) 'Stimulation of adenylate cyclase activity in different areas of human brain by substance P'. Neuropharmacology, 14 (8):615-618. [Details]
Duffy MJ, Mulhall D, Powell D; (1975) 'Subcellular distribution of substance P in bovine hypothalamus and substantia nigra'. Journal of neurochemistry, 25 (3):305-307. [Details]
Duffy MJ, Duffy G; (1977) 'Peroxidase activity as a possible marker for a functional oestradiol receptor in human breast tumours [proceedings]'. Biochemical Society Transactions, 5 (6):1738-1739. [Details]
Duffy MJ, Duffy GJ; (1977) 'Measurement of estradiol receptors in human breast tumors by polyacrylamide gel electrophoresis'. Clinica chimica acta; international journal of clinical chemistry, 74 (2):161-166. [Details]
Duffy MJ, Duffy GJ; (1977) 'Estradiol receptors and glucose-6-phosphate dehydrogenase activity in human breast tumors'. Clinica chimica acta; international journal of clinical chemistry, 74 (2):167-171. [Details]
Duffy MJ (2013) 'The war on cancer: are we winning?'. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 34 (3):1275-1284. [DOI] [Details]
Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C (2013) 'Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update'. INT J CANCER, . [DOI] [Details]
Soletormos, G,Duffy, MJ,Hayes, DF,Sturgeon, CM,Barak, V,Bossuyt, PM,Diamandis, EP,Gion, M,Hyltoft-Petersen, P,Lamerz, RM,Nielsen, DL,Sibley, P,Tholander, B,Tuxen, MK,Bonfrer, JMG (2013) 'Design of Tumor Biomarker-Monitoring Trials: A Proposal by the European Group on Tumor Markers'. Clinical Chemistry, 59 :52-59. [DOI] [Details]
Sturgeon CM, Duffy MJ, Walker G (2011) 'The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory'. Annals of Clinical Biochemistry, 48 (Pt 4):295-299. [DOI] [Details]
Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM (2011) 'The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?'. Proteomics, 8 (1). [DOI] [Details]
Duffy MJ (2011) 'Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?'. Annals of Clinical Biochemistry, 48 (Pt 4):310-316. [DOI] [Details]
Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J, Duffy MJ (2011) 'Src: a potential target for the treatment of triple-negative breast cancer'. Annals of Oncology, 22 (10):2234-2240. [DOI] [Details]
Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM (2012) 'Design of Tumor Biomarker-Monitoring Trials: A Proposal by the European Group on Tumor Markers'. Clinical Chemistry, . [DOI] [Details]
Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N (2012) 'Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours'. Breast Cancer Research and Treatment, . [DOI] [Details]
McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O'Donovan N, Duffy MJ (2012) 'ADAM-17: a novel therapeutic target for triple negative breast cancer'. Annals of Oncology, . [DOI] [Details]
Brennan DJ, O'Connor DP, Laursen H, McGee SF, McCarthy S, Zagozdzon R, Rexhepaj E, Culhane AC, Martin FM, Duffy MJ, Landberg G, Ryden L, Hewitt SM, Kuhar MJ, Bernards R, Millikan RC, Crown JP, Jirström K, Gallagher WM (2012) 'The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer'. Oncogene, 31 (30):3483-3494. [DOI] [Details]
Duffy MJ, McGowan PM, Crown J (2012) 'Targeted therapy for triple-negative breast cancer: Where are we?'. INT J CANCER, 131 (11):2471-2477. [DOI] [Details]
Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J (2012) 'Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines'. Annals of Oncology, 23 (7):1788-1795. [DOI] [Details]
Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A, Duffy MJ (2012) 'mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors'. Breast (Edinburgh, Scotland), 21 (2):178-182. [DOI] [Details]
Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, Nicolini A, Haglund C, Holubec L, Fraser CG, Halloran SP; (2011) 'Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper'. INT J CANCER, 128 (1):3-11. [DOI] [Details]
Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V.; (2010) 'Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report'. Annnals of Oncology, 21 :441-447. Available Online [Details]
Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry.; (2010) 'National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers'. Clinical Chemistry, 56 :e1-48. Available Online [Details]
O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.; (2010) 'Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib'. Molecular Cancer Therapy, 9 :1489-502. Available Online [Details]
Duffy MJ, Evoy D, McDermott EW; (2010) 'CA 15-3: uses and limitation as a biomarker for breast cancer'. Clinica chimica acta; international journal of clinical chemistry, 411 (23-24):1869-1874. [DOI] [Details]
Gallagher WM, Lau TY, Power KA, Dijon S, de Gardelle I, McDonnell S, Duffy MJ, Pennington SR, ; (2010) 'Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification'. Journal of Proteome Research, 9 (3):1450-1459. [DOI] [Details]
Pierce A, Saldova R, Abd Hamid UM, Abrahams JL, McDermott EW, Evoy D, Duffy MJ, Rudd PM.; (2010) 'Levels of Specific Glycans Significantly Distinguish Lymph Node-Positive from Lymph Node-Negative Breast Cancer Patients'. Glycobiology, . Available Online [Details]
Duffy MJ, O'Donovan N, Crown J; (2010) 'Use of molecular markers for predicting therapy response in cancer patients'. Cancer Treatment Reviews, . [DOI] [Details]
Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N; (2010) 'Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells'. Annals of Oncology, . [DOI] [Details]
Ryan BM, O'Donovan N, Duffy MJ.; (2009) 'Survivin: a new target for anti-cancer therapy'. Cancer Treatment Reviews, 35 :553-562. Available Online [Details]
Sturgeon CM, Lai LC, Duffy MJ.; (2009) 'Serum tumour markers: how to order and interpret them'. BMJ (Clinical research ed.), 339 . Available Online [Details]
Brennan, D. J., Hewitt, S. M., Rexhepaj, E., O¿Brien, S. L., McSherry, E., O¿Connor, D. P., Fagan, A., Culhane, A. C., Higgins, D. G., Jirstrom, K., Millikan, R. C., Landberg, G., Duffy, M. J., and Gallagher, W. M. ; (2008) 'Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer'. Clinical Cancer Research, 14 (9):2681-2689. [DOI] [Details]
Diamandis EP, Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, ; (2008) 'National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers'. Clinical Chemistry, 54 (12):1-79. [DOI] [Details]
Duffy MJ, McKiernan E, O'Brien K, Grebenchtchikov N, Geurts-Moespot A, Sieuwerts AM, Martens JW, Magdolen V, Evoy D, McDermott E, Crown J, Sweep FC, ; (2008) 'Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA'. Cancer, 99 (10):1644-1650. [DOI] [Details]
Crown J, Duffy MJ, ; (2008) 'A personalized approach to cancer treatment: how biomarkers can help'. Clinical Chemistry, 54 (11):1770-1779. [DOI] [Details]
Gallagher WM, Brennan DJ, O'Brien SL, Fagan A, Culhane AC, Higgins DG, Duffy MJ, ; (2005) 'Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response'. Expert Opinion on Biological Therapy, 8 (NA):1069-1083. [DOI] [Details]
Buggy, Y,Maguire, TM,McGreal, G,McDermott, E,Hill, ADK,O'Higgins, N,Duffy, MJ; (2004) 'Overexpression of the Ets-1 transcription factor in human breast cancer'. Cancer, 91 (NA):1308-1315. [DOI] [Details]
Duffy, MJ,Duggan, C,Keane, R,Hill, ADK,McDermott, E,Crown, J,O'Higgins, N; (2004) 'High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically confirmed breast cancer'. Clinical Chemistry, 50 (NA):559-563. [DOI] [Details]
Sheahan K, Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, ; (1994) 'Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer'. Lancet, 344 (8922):583-584. [Details]
Duffy MJ, Markey GC, Cullen R, Diggin P, Hill AD, Mc Dermott EW, O'Higgins NJ, ; (2009) 'Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer'. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 30 (4):171-175. [DOI] [Details]
McGowan PM, Duffy MJ, McKiernan E, O'Donovan N, ; (2009) 'Role of ADAMs in cancer formation and progression'. Clinical Cancer Research, 15 (4):1140-1144. [DOI] [Details]
Schmitt M, Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, Brunner N, Foekens JA, ; (2009) 'Methylated genes as new cancer biomarkers'. European Journal of Cancer, 45 (3):335-346. [DOI] [Details]
Martens JW, Span PN, Sieuwerts AM, Heuvel JJ, Spyratos F, Duffy MJ, Eppenberger-Castori S, Vacher S, O'Brien K, McKiernan E, Pierce A, Vuaroqueaux V, Foekens JA, Sweep FC, ; (2009) 'Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: an EU-FP6 supported study of members of the EORTC - PathoBiology Group'. European Journal of Cancer, 45 (1):74-81. [DOI] [Details]
Duffy MJ, Sturgeon CM, Lai LC, ; (2009) 'Serum tumour markers: how to order and interpret them'. BMJ (Clinical research ed.), 339 . [Details]
McGowan PM, Duffy MJ, McKiernan E, O'Donovan N, ; (2009) 'The role of ADAMs in disease pathophysiology'. Clinica Chimica Acta, 403 (1-2):31-36. [Details]
Gallagher WM, Lanigan F, McKiernan E, Brennan DJ, Hegarty S, Millikan RC, McBryan J, Jirstrom K, Landberg G, Martin F, Duffy MJ, ; (2009) 'Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer'. International Journal of Cancer, 124 (9):2088-2097. [DOI] [Details]
O'Donovan N, Browne BC, O'Brien N, Duffy MJ, Crown J, ; (2009) 'HER-2 signaling and inhibition in breast cancer'. Current Cancer Drug Targets, 9 (3):419-438. [Details]
Brennan, D. J., Rexhepaj, E., O'Brien, S. L., McSherry, E., O'Connor, D. P., Fagan, A., Culhane, A. C., Higgins, D. G., Jirstrom, K., Millikan, R. C., Landberg, G., Duffy, M. J., Hewitt, S. M., Gallaghe, W. M., ; (2008) 'Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer'. Clinical Cancer Research, 14 (9):2681-2689. [Details]
McGowan, P. and Duffy, M.J.; (2008) 'Matrix metalloproteinases expression and outcome in patients with breast cancer: analysis of a published database'. Annals of Oncology, 19 :1566-1572. [Details]
Duffy, M.J. and McGowan, P.; (2008) 'Cancer invasion and metastasis'. Journal of Pathology, 214 :283-293. [Details]
Krajewska, M, et al.; (2008) 'Bcl-B expression in human epithelial and non-epithelial malignancies'. Clinical Cancer Research, 14 :3011-3021. [Details]
McGowan, P, et al.; (2008) 'ADAM17 predicts adverse outcome in patients with breast cancer'. Annals of Oncology, 19 :1075-1081. [Details]
Duffy MJ, McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, Evoy D, O'Higgins N, Crown J, ; (2008) 'ADAM-17 predicts adverse outcome in patients with breast cancer'. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 6 (NA):1075-1081. [DOI] [Details]
OBrien, SL, Fagan, A, Fox, EJP, Millikan, RC, Culhane, AC, Brennan, DJ, McCann, AH, Hegarty, S, Moyna, S, Duffy, MJ, Higgins, DG, Jirstrom, K, Landberg, G, Gallagher, WM, ; (2007) 'CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer'. INT J CANCER, 120 :1434-1443. [Details]
Duffy, MJ, ; (2007) 'Role of tumor markers in patients with solid cancers: A critical review'. EUR J INTERN MED, 18 :175-184. [Details]
Browne, B, ODonovan, N, Venkatesan, N, Pegram, M, Clynes, M, Duffy, MJ, Crown, J, Slamon, DJ, ; (2007) 'The role of insulin-like growth factor I receptor (IGF-IR) in trastuzumab resistance in breast cancer cells'. ANTICANCER RES, 27 :1379-1379. [Details]
O'Brien, N., O'Donovan, N., Foley, D., Hill, A. D. K., McDermott, E., O'Higgins, N., Duffy, M. J., ; (2007) 'Use of a panel of novel genes for differentiating breast cancer from non-breast tissues'. Tumor Biology, 28 (6):312-317. [Details]
Culleton, J, O'Brien, N, Ryan, BM, Hill, ADK, McDermott, E, O'Higgins, N, Duffy, MJ, ; (2007) 'Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer'. INT J CANCER, 120 (5):1087-1092. [DOI] [Details]
Duffy, MJ, ODonovan, N, Brennan, DJ, Gallagher, WM, Ryan, BM, ; (2007) 'Survivin: A promising tumor biomarker'. CANCER LETT, 249 :49-60. [Details]
Culleton, J, OBrien, N, Ryan, BM, Hill, ADK, McDermott, E, OHiggins, N, Duffy, MJ, ; (2007) 'Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer'. INT J CANCER, 120 :1087-1092. [Details]
Duffy, MJ, van Dalen, A, Haglund, C, Hansson, L, Holinski-Feder, E, Klapdor, R, Lamerz, R, Peltomaki, P, Sturgeon, C, Topolcan, O, ; (2007) 'Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use'. European Journal of Cancer, 43 :1348-1360. [Details]
Gallagher WM, Lau TY, O'Connor DP, Brennan DJ, Duffy MJ, Pennington SR, ; (2007) 'Breast cancer proteomics: clinical perspectives'. Expert Opinion on Biological Therapy, 2 (NA):209-219. [DOI] [Details]
Topolcan O, Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, ; (2007) 'Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use'. European Journal of Cancer, 9 (NA):1348-1360. [DOI] [Details]
McGowan, PM, Ryan, BM, Hill, ADK, McDermott, E, OHiggins, N, Duffy, MJ, ; (2007) 'ADAM-17 expression in breast cancer correlates with variables of tumor progression'. Clinical Cancer Research, 13 :2335-2343. [Details]
Gallagher WM, Brennan DJ, Kelly C, Rexhepaj E, Dervan PA, Duffy MJ, ; (2007) 'Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer'. Cancer Genomics Proteomics, 3 (NA):121-134. [Details]
Savinov, AY, Remacle, SG, Golubkov, RS, Krajewska, M, Kennedy, S, Duffy, MJ, Rozanov, DV, Krajewski, S, Strongin, AY, ; (2006) 'Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients'. Cancer Research, 66 (5):2716-2724. [Details]
Duffy MJ, Buggy Y, Maguire TM, McDermott E, Hill AD, O'Higgins N, ; (2006) 'Ets2 transcription factor in normal and neoplastic human breast tissue'. European Journal of Cancer, 4 (NA):485-491. [DOI] [Details]
O'Brien SL, Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Rydén L, Gallagher WM, ; (2006) 'CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance'. Clinical Cancer Research, 21 (NA):6421-6431. [DOI] [Details]
Ryan, BM, Konecny, GE, Kahlert, S, Wang, HJ, Untch, M, Meng, G, Pegram, MD, Podratz, KC, Crown, J, Slamon, DJ, Duffy, MJ, ; (2006) 'Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1'. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 17 (4):597-604. [Details]
Brennan, DJ, Jirstrom, K, Kronblad, A, Millikan, RC, Landberg, G, Duffy, MJ, Ryden, L, Gallagher, WM, O'Brien, SL, ; (2006) 'CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance'. Clinical Cancer Research, 12 (21):6421-6431. [DOI] [Details]
Duffy MJ, ; (2006) 'Serum tumor markers in breast cancer: are they of clinical value?'. Clinical Chemistry, 3 (NA):345-351. [DOI] [Details]
Duffy MJ, ; (2006) 'Estrogen receptors: role in breast cancer'. Critical reviews in clinical laboratory sciences, 4 (NA):325-347. [DOI] [Details]
Duffy MJ, Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, ; (2006) 'Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1'. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 4 (NA):597-604. [DOI] [Details]
Al-Azawi, D, Kelly, G, Myers, E, McDermott, EW, Hill, ADK, Duffy, MJ, O Higgins, N, ; (2006) 'CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer'. BMC Cancer, 6 (NA). [DOI] [Details]
Duffy MJ, Kelly LM, Buggy Y, Hill A, O'Donovan N, Duggan C, McDermott EW, O'Higgins NJ, Young L, ; (2005) 'Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes'. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 4 (NA):213-216. [DOI] [Details]
Duffy MJ, ; (2005) 'Predictive markers in breast and other cancers: a review'. Clinical Chemistry, 3 (NA):494-503. [DOI] [Details]
Ryan, B, O'Donovan, N, Browne, B, O'Shea, C, Crown, J, Hill, ADK, McDermott, E, O'Higgins, N, Duffy, MJ, ; (2005) 'Expression of survivin and its splice variants survivin-2B and survivin-Delta Ex3 in breast cancer'. British Journal of Cancer, 92 (1):120-124. [DOI] [Details]
Krajewska, M, Kim, H, Shin, E, Kennedy, S, Duffy, MJ, Wong, YF, Marr, D, Mikolajczyk, J, Shabaik, A, Meinhold-Heerlein, I, Huang, XS, Banares, S, Hedayat, H, Reed, JC, Krajewski, S, ; (2005) 'Tumor-associated alterations in caspase-14 expression in epithelial malignancies'. Clinical Cancer Research, 11 (15):5462-5471. [Details]
Zwirner M, Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, ; (2005) 'CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use'. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 5 (NA):679-691. [DOI] [Details]
Roddam, AW, Duffy, MJ, Hamdy, FC, Ward, AM, Patnick, J, Price, CP, Rimmer, J, Sturgeon, C, White, P, Allen, NE, ; (2005) 'Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis'. EUR UROL, 48 (3):386-399. [Details]
O'Brien, NA, O'Donovan, N, Ryan, B, Hill, ADK, McDermott, E, O'Higgins, N, Duffy, MJ, ; (2005) 'Mammaglobin A in breast cancer: Existence of multiple molecular forms'. INT J CANCER, 114 (4):623-627. [DOI] [Details]
Grebenchtchikov, N, Maguire, TM, Riisbro, R, Geurts-Moespot, A, O'Donovan, N, Schmitt, M, McGreal, G, McDermott, E, O'Higgins, N, Brunner, N, Sweep, CGJ, Duffy, MJ, ; (2005) 'Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: An EORTC Receptor and Biomarker Group collaboration'. Oncology Reports, 14 (1):235-239. [Details]
Duffy, MJ, Bonfrer, JM, Kulpa, J, Rustin, GJS, Soletormos, G, Torre, GC, Tuxen, MK, Zwirner, M, ; (2005) 'CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use'. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 15 (5):679-691. [Details]
Duffy MJ, ; (2004) 'The urokinase plasminogen activator system: role in malignancy'. Current Pharmaceutical Design, 1 (NA):39-49. [Details]
Duffy MJ, ; (2004) 'Evidence for the clinical use of tumour markers'. Annals of Clinical Biochemistry, Pt 5 (NA):370-377. [DOI] [Details]
Schmitt, M, Harbeck, N, Daidone, MG, Brunner, N, Duffy, MJ, Foekens, JA, Sweep, FCGJ, ; (2004) 'Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: Tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer'. International Journal of Oncology, 25 (5):1397-1406. [Details]
Duffy, MJ, Duggan, C, ; (2004) 'The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer'. Clinical Biochemistry, 37 (7):541-548. [Details]
Duffy, MJ, Lynn, DJ, Lloyd, AT, O'Shea, CM, ; (2003) 'The ADAMs family of proteins: from basic studies to potential clinical applications'. Journal of Thrombosis and Haemostasis, 89 (4):622-631. [Details]
Duffy, MJ, van Dalen, A, Haglund, C, Hansson, L, Klapdor, R, Lamerz, R, Nilsson, O, Sturgeon, C, Topolcan, O, ; (2003) 'Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines'. European Journal of Cancer, 39 (6):718-727. [Details]
Duffy MJ, O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, O'Higgins N, ; (2003) 'Expression of ADAM-9 mRNA and protein in human breast cancer'. INT J CANCER, 6 (NA):754-761. [DOI] [Details]
Mofidi, R, Walsh, R, Ridgway, PF, Crotty, T, McDermott, EW, Keaveny, TV, Duffy, MJ, Hill, ADK, O'Higgins, N, ; (2003) 'Objective measurement of breast cancer oestrogen receptor status through digital image analysis'. European Journal of Surgical Oncology, 29 (1):20-24. [Details]
Look, M, van Putten, W, Duffy, M, Harbeck, N, Christensen, IJ, Thomssen, C, Kates, R, Spyratos, F, Ferno, M, Eppenberger-Castori, S, Sweep, CGJF, Ulm, K, Peyrat, JP, Martin, PM, Magdelenat, H, Brunner, N, Duggan, C, Lisboa, BW, Bendah, PO, Quillien, V, Daver, A, Ricolleau, G, Meijer-Van Gelder, M, Manders, P, Fiets, WE, Blankenstein, M, Broet, P, Romain, S, Daxenbichler, G, Windbichler, G, Cufer, T, Borstnar, S, Kueng, W, Beex, L, Klijn, J, O'Higgins, N, Eppenberger, U, Janicke, F, Schmitt, M, Foekens, J, ; (2003) 'Pooled analysis of prognostic impact of uPA and PAI-I in breast cancer patients'. Journal of Thrombosis and Haemostasis, 90 (3):538-548. [Details]
Greene, LM, Twal, WO, Duffy, MJ, McDermott, EW, Hill, AD, O'Higgins, NJ, McCann, A, Dervan, P, Argraves, W, Gallagher, WM, ; (2003) 'Elevated expression and altered processing of fibulin-1 protein in human breast cancer'. British Journal of Cancer, 88 (6):871-878. [Details]
O'Donovan, N, Crown, J, Stunell, H, Hill, ADK, McDermott, E, O'Higgins, N, Duffy, MJ, ; (2003) 'Caspase 3 in breast cancer'. Clinical Cancer Research, 9 (2):738-742. [Details]
O'Brien, N, Maguire, TM, O'Donovan, N, Lynch, N, Hill, ADK, McDermott, E, O'Higgins, N, Duffy, MJ, ; (2002) 'Mammaglobin A: A promising marker for breast cancer'. Clinical Chemistry, 48 (8):1362-1364. [Details]
Duffy MJ, ; (2002) 'Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies'. Clinical Chemistry, 8 (NA):1194-1197. [Details]
Duffy MJ, ; (2002) 'Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers'. Biochemical Society Transactions, 2 (NA):207-210. [DOI] [Details]
Duffy MJ, ; (2001) 'Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?'. Clinical Chemistry, 4 (NA):624-630. [Details]
Cullen, R, Maguire, TM, McDermott, EW, Hill, ADK, O'Higgins, NJ, Duffy, MJ, ; (2001) 'Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer'. European Journal of Cancer, 37 (9):1118-1122. [Details]
Duffy MJ, ; (2001) 'Clinical uses of tumor markers: a critical review'. Critical reviews in clinical laboratory sciences, 3 (NA):225-262. [Details]
Duffy MJ, ; (2001) 'Biochemical markers in breast cancer: which ones are clinically useful?'. Clinical Biochemistry, 5 (NA):347-352. [Details]
Duffy, MJ, Maguire, TM, Hill, A, McDermott, E, O'Higgins, N, ; (2000) 'Metalloproteinases: role in breast carcinogenesis, invasion and metastasis'. Breast Cancer Research, 2 (4):252-257. [Details]
Hanemaaijer, R, Verheijen, JH, Maguire, TM, Visser, H, Toet, K, McDermott, E, O'Higgins, N, Duffy, MJ, ; (2000) 'Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors'. INT J CANCER, 86 (2):204-207. [Details]
O'Higgins N, Duffy MJ, Shering S, Sherry F, McDermott E, ; (2000) 'CA 15-3: a prognostic marker in breast cancer'. The International journal of biological markers, 4 (NA):330-333. [Details]
O'Higgins N, Duffy MJ, Maguire TM, McDermott EW, ; (1999) 'Urokinase plasminogen activator: a prognostic marker in multiple types of cancer'. Journal of surgical oncology, 2 (NA):130-135. [Details]
Duffy MJ, ; (1999) 'CA 15-3 and related mucins as circulating markers in breast cancer'. Annals of Clinical Biochemistry, (NA):579-586. [Details]
Shering, SG, Sherry, F, McDermott, EW, O'Higgins, MJ, Duffy, MJ, ; (1998) 'Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma'. Cancer, 83 (12):2521-2527. [Details]
O'Higgins NJ, Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, ; (1998) 'Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease'. Clinical Chemistry, 6 Pt 1 (NA):1177-1183. [Details]
Chenard, MP, OSiorain, L, Shering, S, Rouyer, N, Lutz, Y, Wolf, C, Basset, P, Bellocq, JP, Duffy, MJ, ; (1996) 'High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma'. INT J CANCER, 69 (6):448-451. [Details]
DUFFY, MJ, BROUILLET, JP, REILLY, D, MCDERMOTT, E, OHIGGINS, N, FENNELLY, JJ, MAUDELONDE, T, ROCHEFORT, H, ; (1991) 'CATHEPSIN-D CONCENTRATION IN BREAST-CANCER CYTOSOLS - CORRELATION WITH BIOCHEMICAL, HISTOLOGICAL, AND CLINICAL FINDINGS'. Clinical Chemistry, 37 (1):101-104. [Details]
                                                                                             

Research

Research Interests

Molecular biomarkers in breast cancer: use of novel biomarkers for aiding the early diagnosis of breast cancer, determining prognosis and predicting reponse to therapy.
 
Development of novel therapeutics for breast cancer. 

Research Projects

Sponsor : Irish Cancer Society (ICS)
Title : The role of ADAMs in mediating resistance to HER-targeted therapies
Start Date / End Date : 01-DEC-11 / 30-NOV-14
Sponsor : The Wellcome Trust (WT)
Title : The role of ADAMs in mediating resistance to anti-HER agents
Start Date / End Date : 04-JUN-13 / 26-JUL-13
Sponsor : University College Dublin (UCD)
Title : ADAM10: A NEW PLAYER IN BREAST CANCER PROGRESSION?
Start Date / End Date : 01-MAY-12 / 31-OCT-13
Sponsor : Science Foundation Ireland (SFI)
Title : Molecular therapeutics for cancer: translational research to individualise therapy with targeted agents
Start Date / End Date : 01-OCT-09 / 01-OCT-12
   

Teaching

Teaching Philosophy

 Cancer biology to BSc Hons course in Biochemistry and Pharmacology.

 Tumor biomarkers to postgraduate Nursing students  


         

Collaborators

Internal Collaborators

Mr Enda McDermott, St Vincent's University Hospital,

Professor John Crown, St Vincent's University Hospital,

Professor Liam Gallagher, UCD

Dr Norma O'Donovan, DCU

External Collaborators

Dr Neil O'Brien and Professor Denis Slamon, UCLA, Los Angeles
 
Prof G. Murphy, University of Cambridge 
 
Dr A Kong, University of Oxford